.png)
GrayMatters Health
FDA-cleared EEG neurofeedback (Prism) for PTSD; IDF-origin, MTEC member
Latest event found: 14 Sep 2026 · about 1 month ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
GrayMatters Health is moving from an FDA-cleared PTSD adjunct into a broader biomarker-powered interventional psychiatry platform, with emphasis on clinical adoption, payer access, clinic enablement, and expansion into depression and additional psychiatric indications. Recent product, research, and patient-utilization milestones indicate active commercialization rather than a purely R&D-stage posture.
Efficiency Ratio
The company appears to be producing substantial clinical, regulatory, research, and product output from a relatively small recorded workforce, indicating strong resource-to-output efficiency but limited evidence of scaled operational capacity.
Evidence Signals
The company highlighted collaboration with leading mental health institutions to research and evaluate Prism for additional psychiatric disorders.
The company announced a payer strategy intended to accelerate patient access to biomarker-powered Prism treatment for PTSD.
The company launched Prism Imagine, extending its biomarker-powered psychiatry product portfolio.
The company reported reaching 10,000 Prism PTSD patient sessions.
The company announced research expanding the scientific validity and clinical impact of fMRI-informed biomarkers.
The company announced Prism360, offering financing, benefits investigation, prior authorization, and operational support for clinics providing Prism.
- About
- Israeli digital mental-health company (HQ Haifa, Israel; founded 2016 by Oded Kraft (CEO), Rani Cohen (executive chairman) and Shai Attia), developing self-neuromodulation therapies. Its FDA-cleared flagship Prism is a prescription neurofeedback system — an EEG cap plus software that trains patients to self-regulate an amygdala-derived, fMRI-informed biomarker to control their emotional response, as an adjunctive treatment for PTSD (a depression protocol is in trials). The PTSD biomarker was developed from research on IDF soldiers scanned before and after combat. Prism is in use in US hospitals and Germany, and GrayMatters is a member of the US MTEC (USAMRDC) medical consortium. Opens a warfighter/veteran behavioral-health lane — one of the largest DoD/VA medical demand areas — that the DON medical set otherwise lacks.
- Tags
- #ptsd #neurofeedback #neuromodulation #eeg #behavioralhealth #mentalhealth #veterans #fda #mtec #idforigin #dualuse